SEC Form 4 · accession 0001193125-26-291131
Climb Bio, Inc. · CLYM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Aoife Brennan
Officer — President and CEO · Director
Period of report
Jun 27, 2026
Accepted (ET)
Jun 30, 2026 · 7:50 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001768446
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 27, 2026 | M | 68,750 | — | A | 118,633 | D | |
| Common StockF4 | Jun 29, 2026 | S | 30,902 | $13.17 | D | 87,731 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF5,F6 | — | Jun 27, 2026 | M | 68,750 | D | — | — | Common Stock | 68,750 | 137,500 | D |
Explanation of responses
- F1Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock
- F2Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan.
- F3The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.
- F4The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- F5Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F6The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.